Karl D. Lewis
卡尔·刘易斯
MD
Professor of Medicine; Co-Director, Melanoma Program医学教授；黑色素瘤项目联合主任
👥Biography 个人简介
Karl Lewis, MD is Professor of Medicine and Co-Director of the Melanoma Program at the University of Colorado Cancer Center, and a leading investigator in personalized neoantigen cancer vaccines for melanoma. He was a principal investigator in the KEYNOTE-942 phase IIb trial evaluating mRNA-4157/V940 (Moderna/Merck personalized neoantigen vaccine) combined with pembrolizumab, which demonstrated significant improvement in recurrence-free survival versus pembrolizumab alone in high-risk resected melanoma and established a new paradigm for vaccine-immunotherapy combinations.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
mRNA-4157/V940 Neoantigen Vaccine in Resected Melanoma
Served as a leading investigator in KEYNOTE-942, the phase IIb trial demonstrating that adjuvant mRNA-4157/V940 combined with pembrolizumab significantly improved recurrence-free and distant metastasis-free survival versus pembrolizumab alone in high-risk resected stage III/IV melanoma.
Personalized Vaccine Development Framework
Contributed to establishing the computational pipeline and manufacturing protocols for patient-specific neoantigen vaccine design using tumor whole-exome sequencing and HLA typing to identify immunogenic mutant peptides.
Novel Combination Immunotherapy Clinical Trials
Led multiple early-phase trials of novel immune co-stimulatory and checkpoint agents combined with PD-1 inhibitors in melanoma, expanding the therapeutic toolkit beyond first-generation checkpoint blockade.
Representative Works 代表性著作
Adjuvant pembrolizumab plus mRNA-4157/V940 versus pembrolizumab plus placebo in resected high-risk melanoma (KEYNOTE-942)
Lancet (2023)
Phase IIb randomized trial showing significant improvement in recurrence-free survival with personalized neoantigen mRNA vaccine combined with pembrolizumab in stage III/IV resected melanoma.
Phase I study of mRNA-4157 personalized cancer vaccine alone or in combination with pembrolizumab
Journal of Clinical Oncology (2022)
First-in-human study establishing safety, tolerability, and immunogenicity of patient-specific neoantigen mRNA vaccine in resected solid tumors.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-20 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 卡尔·刘易斯 的研究动态
Follow Karl D. Lewis's research updates
留下邮箱，当我们发布与 Karl D. Lewis（University of Colorado Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment